BIO

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, its products advance the discovery process and improve healthcare. Bio-Rad's customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020.
CEO
Norman Schwartz
Employees
8000
Headquarters

1000 Alfred Nobel Dr
Hercules, California 94547-1811
Phone: 15107247000
www.bio-rad.com

News

OncoCyte''s Innovative Approach: Potential in Precision Diagnostics
Jun 05, 2024 11:00am

Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects. Amidst these challenges, OncoCyte Corporation (NASDAQ: OCX ) has emerged as an innovative player in the precision diagnostics market. The company''s tests enhance clinical outcomes for patients undergoing organ transplants and cancer treatments. With recent strategic partnerships and regulatory advancements, OncoCyte has spearheaded transformative advancements in the field. OCX’s product portfolio includes VitaGraft, a clinical blood-based test for monitoring solid organ transplants, and GraftAssure, a research-use-only test for the same purpose.


Source:The North America Newswire
Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
May 30, 2024 13:00pm

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. Ms. Engelhardt joins Bio-Rad from Cepheid, a wholly owned subsidiary of Danaher Corporation and a Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
GlycoNex to Participate in 2024 BIO International Convention
May 30, 2024 10:00am


Source:Kwhen Finance
BIO 2024 Sets the Stage for Taiwan''s Biotech Industry to Shine
May 30, 2024 09:56am


Source:Kwhen Finance
Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
May 23, 2024 20:15pm

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 10:30 AM Eastern Time (7:30 AM Pacific Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Fzata is a Start-Up Stadium Finalist at BIO 2024
May 14, 2024 18:04pm


Source:Kwhen Finance
Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript
May 08, 2024 03:16am

No summary available.


Source:Seeking Alpha
BIO Stock Earnings: Bio-Rad Laboratories Beats EPS, Misses Revenue for Q1 2024
May 08, 2024 00:54am

Bio-Rad Laboratories (NYSE: BIO ) just reported results for the first quarter of 2024. Bio-Rad Laboratories reported earnings per share of $2.29. This was above the analyst estimate for EPS of $2.15. The company reported revenue of $610.82 million. This was 1.34% worse than the analyst estimate for revenue of $619.09 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.


Source:InvestorPlace
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
May 07, 2024 22:10pm

Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.


Source:Reuters
Bio-Rad Labs Q1 2024 Earnings Preview
May 06, 2024 21:35pm

Bio-Rad Labs is set to announce Q1 earnings on May 7th. The consensus estimates for EPS and revenue show a decline.


Source:Seeking Alpha